[en] [en] BACKGROUND: The basis of the less severe clinical presentation of coronavirus disease 2019 (COVID-19) in children as compared with adults remains incompletely understood. Studies have suggested that a more potent boosting of immunity to endemic common cold coronaviruses (HCoVs) may protect children.
METHODS: To test this hypothesis, we conducted a detailed analysis of antibodies induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children aged 2 months to 14 years.
RESULTS: Younger children had higher titers of antibodies to SARS-CoV-2 receptor binding domain (RBD), S1 but not S2 domain, and total spike (S) protein, higher avidity RBD immunoglobulin G, and higher titers of neutralizing and complement-activating antibodies as compared with older children. In contrast, older children had higher titers of antibodies to HCoVs, which correlated with antibodies to the SARS-CoV-2 S2 domain but not with neutralizing or complement-activating antibodies.
CONCLUSIONS: These results reveal a unique capacity of young children to develop effector antibody responses to SARS-CoV-2 infection independently of their immunity to HCoVs.
Thiriard, Anais; Institute for Medical Immunology, and ULB-Center for Research in Immunology, Université Libre de Bruxelles, Charleroi, Belgium
Heyndrickx, Leo; Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine Antwerp, Antwerp, Belgium
Georges, Daphnée ; Université de Liège - ULiège > Integrative Biological Sciences (InBioS) ; Institute for Medical Immunology, and ULB-Center for Research in Immunology, Université Libre de Bruxelles, Charleroi, Belgium
Van den Wijngaert, Sigi; Laboratoire Hospitalier Universitaire de Bruxelles (LHUB), Brussels, Belgium
Olislagers, Véronique; Institute for Medical Immunology, and ULB-Center for Research in Immunology, Université Libre de Bruxelles, Charleroi, Belgium
Sharma, Shilpee; Institute for Medical Immunology, and ULB-Center for Research in Immunology, Université Libre de Bruxelles, Charleroi, Belgium
Matagne, André ; Université de Liège - ULiège > Département des sciences de la vie > Enzymologie et repliement des protéines
Ackerman, Margaret E; Thayer School of Engineering, Dartmouth College, Hanover, New Hampshire, USA
Ariën, Kevin K; Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine Antwerp, Antwerp, Belgium ; Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
Goetghebuer, Tessa; Pediatric Department, Saint-Pierre Hospital, Brussels, Belgium ; Institute for Medical Immunology, and ULB-Center for Research in Immunology, Université Libre de Bruxelles, Charleroi, Belgium
Marchant, Arnaud; Institute for Medical Immunology, and ULB-Center for Research in Immunology, Université Libre de Bruxelles, Charleroi, Belgium
Language :
English
Title :
Younger Children Develop Higher Effector Antibody Responses to SARS-CoV-2 Infection.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Preston LE, Chevinsky JR, Kompaniyets L, et al. Characteristics and disease severity of US children and adolescents diagnosed with COVID-19. JAMA Netw Open 2021; 4:e215298.
Brodin P. Why is COVID-19 so mild in children? Acta Paediatr 2020; 109:1082-3.
Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr 2020; 109:1088-95.
Blanchard-Rohner G, Didierlaurent A, Tilmanne A, et al. Pediatric COVID-19: immunopathogenesis, transmission and prevention. Vaccines (Basel) 2021; 9: 1002.
Brodin P. SARS-CoV-2 infections in children: understanding diverse outcomes. Immunity 2022; 55:201-9.
World Health Organization. COVID-19 Disease in Children and Adolescents- Scientific Brief. World Health Organization; 2021.
MacLennan CA, Saul A. Vaccines against poverty. Proc Natl Acad Sci U S A 2014; 111:12307-12.
Kollmann TR, Kampmann B, Mazmanian SK, et al. Protecting the newborn and young infant from infectious diseases: lessons from immune ontogeny. Immunity 2017; 46:350-63.
Heath PT, Culley FJ, Jones CE, et al. Group B Streptococcus and respiratory syncytial virus immunisation during pregnancy: a landscape analysis. Lancet Infect Dis 2017; 17:e223-34.
Abu-Raya B, Edwards KM, Scheifele DW, et al. Pertussis and influenza immunisation during pregnancy: a landscape review. Lancet Infect Dis 2017; 17:e209-22.
Kollmann TR, Marchant A, Way SS. Vaccination strategies to enhance immunity in neonates. Science 2020;368:612-5.
Schultze JL, Aschenbrenner AC. COVID-19 and the human innate immune system. Cell 2021; 184:1671-92.
Vono M, Huttner A, Lemeille S, et al. Robust innate responses to SARS-CoV-2 in children resolve faster than in adults without compromising adaptive immunity. Cell Rep 2021; 37:109773.
Zimmermann P, Curtis N. Why does the severity of COVID-19 differ with age? Pediatric Infect Dis J 2022; 41:e36-45.
Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol 2022; 23:186-93.
Chou J, Thomas PG, Randolph AG. Immunology of SARS-CoV-2 infection in children. Nat Immunol 2022; 23:177-85.
Garrido C, Hurst JH, Lorang CG, et al. Asymptomatic or mild symptomatic SARS-CoV-2 infection elicits durable neutralizing antibody responses in children and adolescents. JCI Insight 2021; 6:e150909.
Yang HS, Costa V, Racine-Brzostek SE, et al. Association of age with SARS-CoV-2 antibody response. JAMA Netw Open 2021; 4:e214302.
Dowell AC, Butler MS, Jinks E, et al. Children develop robust and sustained cross- reactive spike-specific immune responses to SARS-CoV-2 infection. Nat Immunol 2022; 23:40-9.
Lavinder JJ, Ippolito GC. Boosted immunity to the common cold might protect children from COVID-19. Nat Immunol 2022; 23:8-10.
Crowley AR, Natarajan H, Hederman AP, et al. Boosting of cross-reactive antibodies to endemic coronaviruses by SARS-CoV-2 infection but not vaccination with stabilized spike. Elife 2022; 11:e75228.
Pannus P, Neven KY, De Craeye S, et al. Poor antibody response to BioNTech/ Pfizer COVID-19 vaccination in SARS-CoV-2 naïve residents of nursing homes. Clin Infect Dis 2022; 75:e695-704.
Weisberg SP, Connors TJ, Zhu Y, et al. Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. Nat Immunol 2021; 22:25-31.
Renk H, Dulovic A, Seidel A, et al. Robust and durable serological response following pediatric SARS-CoV-2 infection. Nat Commun 2022; 13:128.
Ruedas-López A, Berzosa-Sánchez A, Illán-Ramos M, et al. Longitudinal survey of humoral and cellular response to SARS-CoV-2 infection in children. Microbiol Res 2022; 264:127145.
Han MS, Um J, Lee EJ, et al. Antibody responses to SARS-CoV-2 in children with COVID-19. J Pediatric Infect Dis Soc 2022; 11:267-73.
Yang HS, Costa V, Racine-Brzostek SE, et al. Association of age with SARS-CoV-2 antibody response. JAMA Netw Open 2021; 4:e214302.
Zimmermann P, Curtis N. Coronavirus infections in children including COVID-19. Pediatric Infect Dis J 2020; 39:355-68.
Ariën KK, Heyndrickx L, Michiels J, et al. Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant. NPJ Vaccines 2022; 7:35.
Zimmermann P, Pittet LF, Finn A, et al. Should children be vaccinated against COVID-19? Arch Dis Child 2022; 107:e1.
Zhu F, Jin P, Zhu T, et al. Safety and immunogenicity of a recombinant adenovirus type-5-vectored COVID-19 vaccine with a homologous prime-boost regimen in healthy participants aged 6 years and above: a randomised, double-blind, placebo-controlled, phase 2b trial. Clin Infect Dis 2022; 75:e783-91.
Frenck RW, Klein NP, Kitchin N, et al. Safety, immunogenicity, and efficacy of the BNT162b2 COVID-19 vaccine in adolescents. New Engl J Medicine 2021; 385: 239-50.
Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial. Lancet Infect Dis 2022; 22:196-208.
Crotty S. Hybrid immunity. Science 2021; 372:1392-3.
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
